Clinical report demonstrates CCR4 inhibition with mogamulizumab in refractory CD3-CD4+ hypereosinophilic syndrome, indicating a targeted treatment option for abnormal T-cell clones.
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not.The documents may come from teaching and research institutions in France or abroad, or from public
No takes yet. Share an insight, caveat, or question.
Ledoult et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: